GlassScriptPhysician profile
Michael Chase Chappell
NPI 1326104878
$2,193.18
in general payments reported to CMS, 2019-2025
29 companies · $22.95 in 2025
The $22.95 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $236 · 2021: $65.04 · 2022: $665 · 2023: $589 · 2025: $22.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $270.94 | 2019-2023 | |
| Amgen INC. | $253.10 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $192.25 | 2019-2023 | Qulipta, Vraylar |
| Abbott Laboratories | $176.52 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $125.31 | 2019-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $120.78 | 2019-2022 | |
| Glaxosmithkline, LLC. | $100.72 | 2019-2023 | Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $93.47 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $78.11 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.44 | 2019-2023 | Jardiance, Glyxambi, Synjardy |
| Pfizer INC. | $68.86 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.26 | 2020-2023 | Xifaxan |
| Amarin Pharma, INC. | $58.49 | 2019-2020 | |
| Daiichi Sankyo INC. | $55.08 | 2022-2023 | Injectafer |
| Astellas Pharma US INC | $53.96 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $50.16 | 2022 | |
| Dexcom, INC. | $42.03 | 2022-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $41.28 | 2022-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $38.42 | 2022 | |
| Sanofi-Aventis U.S. LLC | $37.89 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $33.28 | 2022 | |
| Boston Scientific Corporation | $28.67 | 2019-2020 | |
| Exact Sciences Corporation | $27.15 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $25.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.17 | 2022 | |
| Intuity Medical INC | $17.56 | 2022 | |
| Allergan, INC. | $16.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.93 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.10 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chappell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.